About Us

About Tibotec

Tibotec is a pharmaceutical research and development company. Our mission is to be a world leader in the discovery and development of innovative HIV/AIDS drugs and superior anti-infectives for diseases of high unmet medical need.

Recognized as one of the companies at the forefront of HIV research, Tibotec has 3 antiretroviral compounds in clinical development:

TMC114, a protease inhibitor (PI)
TMC125, a non-nucleoside reverse transcriptase inhibitor (NNRTI)
TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI)

The company also has an antituberculosis compound in clinical development, two HCV compounds in clinical development, and several active discovery programs in HIV, hepatitis C virus, and other life-threatening infectious diseases.

The original mission of Tibotec was the discovery of new drug candidates in the field of infectious diseases, including HIV/AIDS. A unique and powerful cell-based HIV drug discovery platform was developed that enabled the screening of thousands of chemical compounds for activity against both HIV and cellular toxicity.

In 1995, Virco was established as a spin-off to improve the management of HIV/AIDS with innovative, new molecular diagnostic tools for HIV resistance testing that would better inform the treatment decisions made by physicians.

In April 2002, Tibotec and Virco were acquired by Johnson & Johnson.

Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., will be responsible for commercializing the antiretroviral products in the United States. Tibotec, a division of Janssen-Cilag, will be responsible for their commercialization in Europe.

Tibotec's main research laboratories are located in Mechelen, Belgium, with offices in Ireland and an operating subsidiary in the USA.

About Virco

Virco is an established research-driven biotechnology company based in Mechelen (Belgium) with US offices in Raritan (New Jersey) and Durham (North Carolina).

Virco scientists were among the first to develop HIV-1 drug resistance tests, and today the company still helps doctors make better therapy decisions for their HIV-1-infected patients by providing innovative and practical diagnostic services for the management of HIV-1 infection.

Virco applies the most advanced technologies in molecular biology, virology, genomics, robotics, and electronic data processing to improve the diagnosis and management of disease. Virco's pioneering work in developing and providing these services results not only from translating cutting-edge technology into practical diagnostic tools but also from active collaborations with doctors, patients, and researchers fighting HIV. We are committed to pioneering optimal disease management and patient care by providing innovative diagnostic services and products.

Print this page

Send to a friend